13/06/2019 02:18:33

Zhang Investor Law Announces a Securities Class Action Lawsuit Ra Medical Systems, Inc. – RMED

NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Ra Medical Systems, Inc. (NYSE: RMED) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Ra Medical’s September 2018 initial public offering (the “IPO”). The lawsuit seeks to recover damages for Ra Medical investors under the federal securities laws.

If you wish to serve as lead plaintiff, you must move the Court no later than August 6, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation follow this https://zhanginvestorlaw.com/join-action-form/?slug=ra-medical-systems-inc&id=1904 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email info@zhanginvestorlaw.com, slee@zhanginvestorlaw.com for information on the class action.

According to the lawsuit, the Registration Statement was false and/or misleading and/or failed to disclose that: (1) Ra Medical’s evaluation of sales personnel candidates was inadequate; (2) Ra Medical’s training program for sales personnel was inadequate; (3) Ra Medical could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) Ra Medical would suffer a shortage of qualified sales personnel; (5) Ra Medical’s manufacturing process could not reasonably support increased catheter production; (6) Ra Medical would suffer production delays; and (7) as a result of the foregoing, defendants’ positive statements about Ra Medical’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class has not been certified.  You may retain counsel of your choice.  You may take no action at this time and be an absent class member.  Your ability to obtain a recovery is not dependent upon being a lead plaintiff.  

Zhang Investor Law represents investors worldwide.  Attorney Advertising.  Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.

99 Wall Street, Suite 232

New York, New York 10005

info@zhanginvestorlaw.com

tel: (800) 991-3756

Zahng-Investor-Law.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Jun
 
I øjeblikket sidder "vinderne" ved folketingsvalget og forhandler regeringsgrundlag. De er enige om ..
44
18 Jun
 
Ingen grund til at flytte, de fleste har ikke råd, det er altid middelklassen det rammer og alligeve..
34
20 Jun
 
Måske jeg er den eneste, men savner Alpehue og hans gode indlæg... er han her under et andet alias? ..
23
23 Jun
 
Kære Nets-formand, du er i Danmark, ikke USA Vi er et samfund, hvor få har for meget og færre for li..
20
21 Jun
VELO
Mangel på to tacrolimus - konvertere pat. til Envarsus   I USA konvertere de patienter til Envarsus ..
20
21 Jun
 
@ckt - synes egentlig det havde vaeret bedre, du ikke havde skrevet noget overhovedet..
20
19 Jun
OMXC25
  De vil aldrig få penge nok. Jeg vil tro, at der aldrig er tilført de offentlige kasser flere penge..
20
20 Jun
CHEMM
ChemoMetec opjusterer forventningerne til omsætningen og driftsresultatet som følger af højere forve..
19
21 Jun
VELO
Ser ud til at man omkring 1 juli starter et nyt forsøg op med Envarsus hvor man tilsyneladende forve..
17
18 Jun
AMBU-B
Jeg er rigtig tilfred med de udmeldinger JJG kommer med idag. Det giver ro over deres udmeldinger, o..
17

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
2
Global Arena Holding Inc. (GAHC), Files First Quarter 10Q, and Updates Shareholders on Subsidiaries
3
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eros International Plc (NYSE: EROS) and Encourages Eros Investors to Contact the Firm
4
Hofseth Biocare ASA: Signed Letter of Intent with Garden of Life® for exclusive use of CollaGo® and ProGo® in the US market
5
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2019 23:36:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB5 - 2019-06-25 00:36:04 - 2019-06-24 23:36:04 - 1000 - Website: OKAY